Genomic Services That Power Precision Medicine
With over a decade of expertise, NeoGenomics delivers comprehensive genomic testing and real-world oncology data solutions empowering pharma partners’ drug development and clinical trial programs with precision and speed. All our services are performed under extensive quality control for use in translational research, discovery, and clinical trials.
Your Gateway to Breakthroughs in Genomics
We offer a comprehensive suite of genomic technologies and data-driven solutions, including:
- Next-generation sequencing
- qPCR and ddPCR
- Sanger sequencing
- Multiplexed gene expression
- Microarrays
- Real-world oncology data
Our services are delivered as an end-to-end solution, from extraction to data analysis, and are validated as RUO or LDT across multiple sample types to ensure accuracy, reproducibility, and a rapid turnaround time.
Led by seasoned bioinformaticians and scientists, our team offers precise data analysis, meaningful interpretation, and expert consulting to support your program needs.
Custom assay development and tailored workflows are available, including assay transfer for exploratory and enrollment studies.
Next-Generation Sequencing
Next-Generation Sequencing
Flexible, high-throughput sequencing across platforms:
- Illumina: NovaSeq X, NovaSeq 6000, NextSeq 500/550, MiSeq
- Thermo Fisher: Ion Torrent Genexus, PGM Dx and Ion S5 Prime
Comprehensive Genomic Profiling
- Identify rare variants down to 3% allele frequencies - lower option for exploratory studies
- Validated in-house NGS assays for solid tumors and hematologic malignancies supporting clinical trials and translational research
- Validated data analysis pipelines for DNA and RNA variant detection, tumor fraction estimation, clonality and resistance tracking, longitudinal monitoring, visualization, or custom analyses
Neo RaDaR® ST for Pharma Partners
Unlock the power of tumor-informed MRD detection with the RaDaR ST assay, delivering real-time molecular insights and high-sensitivity ctDNA analysis to identify residual disease with confidence.
- Track tumor dynamics in real time
- Design smarter, more adaptive clinical trials
- Accelerate real-world impact across oncology pipelines
Learn more about the RaDaR ST assay and how it's redefining MRD-driven decision-making
TSO 500 Portfolio
Illumina TSO 500 HT Tissue and TSO 500 ctDNA v2 for broad genomic profiling to support patient enrollment, stratification, and exploratory analysis.
We also offers RareCyte® liquid biopsy service.
Exploratory NGS
Suite of NGS-validated assays for exploratory and research purposes with full bioinformatics support for comprehensive analysis. Includes customizable workflow options such as increased coverage to enhance sensitivity.
- Whole Genome Sequencing (WGS)
- Whole Exome Sequencing (WES)
- Whole Transcriptome Sequencing (WTS)
- RNA Exome Sequencing
qPCR/ddPCR
qPCR/ddPCR
A wide range of well-established PCR platforms to support your programs, including:
- Applied Biosystems™ QuantStudio™ 6/7
- Roche cobas® 4800
- Qiagen Rotor-Gene® Q MDx
- Bio-Rad Droplet Digital™ PCR QX200
- Applied Biosystems 3730xl and 3500 Dx
Our multidisciplinary teams spanning assay development, scientific, and operational functions are equipped to support any off-the-shelf qPCR or ddPCR assays, de novo assay development, and novel DNA/RNA targets, including custom assay transfer and development.
qPCR
- Pre- and post-analytical processes including pathology review, nucleic acid extraction, QC, and data interpretation
- Assay validation tiered for research through to clinical trial testing
- Custom reportable including raw Ct values to fully analyzed data
ddPCR
- Precise and sensitive digital PCR solutions for a wide variety of applications such as quantification of low abundance variants, copy number variation, and gene expression
- Droplet partitioning reducing bias from potential PCR inhibitors
- Efficient assay design without the need for standard curves
Fragment analysis of PCR amplicons is also supported, including:
- Microsatellite Instability (MSI)
- DNA/RNA targets such as FLT3, NPM1, and ABL1
Sanger Sequencing
Powered by Applied Biosystems 3730xl Genetic Analyzer, our Sanger sequencing services deliver simplicity, scalability, and speed. Detect single nucleotide variants, small insertions/deletions, and test known familial variants.
- NGS results confirmation for added confidence
- Germline SNP genotyping
- Sequence confirmation of various constructs
- Plasmids
- Viral vectors or genomes
- mRNA-based therapeutics
Multiplex Gene Expression
NanoString nCounter® and GeoMx DSP technologies for translational research and spatial omics service
nCounter® Service
The nCounter® system digitally counts targets and enables biopharma partners to detect and multiplex up to 800 genes in a single reaction, without amplification, delivering superior performance and reproducibility.
- Efficiently profile gene expression patterns to identify potential drug targets, predict treatment response, and classify tumors based on their molecular subtypes.
- Provide valuable data to assess treatment efficacy and guide personalized medicine approaches.
Analytically validated nCounter® panels
Suite of analytically validated panels tested for accuracy, precision, specificity, and RNA input range and rigorously assessed using a variety of samples.
Panel Plus customization
Panel Plus solution allows customization of any validated gene expression panel by adding 6 to 55 user-defined probes, giving you the flexibility to tailor assays to your research needs.
Microarray
NeoGenomics offers Illumina microarrays services with the Global Screening Array validated for research and exploratory studies. This array is designed for precision medicine research and population genomics. We can qualify additional arrays as studies require, including for cytogenetics.
- Germline genotyping of SNPs or copy number
- Molecular cytogenetics (copy number genome wide)
Real-World Data
Our real-world data services empower pharma partners with deep, actionable insights derived from diverse patient populations. Our genomic and clinical datasets enable precision targeting and support data-driven decision-making across the drug development lifecycle.
Key highlights:
- Comprehensive genomic and clinical data from diverse populations
- Longitudinal patient insights to inform study design and strategy
- Advanced analytics for biomarker discovery and validation
- Timely data access for responsive decision-making
- Customizable data solutions tailored to specific research needs
Expertise You Can Trust. Resources You Can Act On.
Explore our webinars, white papers, and other valuable resources